Determination That TESSALON (Benzonatate) Capsules and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Federal Register, Volume 80 Issue 138 (Monday, July 20, 2015)
Federal Register Volume 80, Number 138 (Monday, July 20, 2015)
Notices
Pages 42828-42829
From the Federal Register Online via the Government Publishing Office www.gpo.gov
FR Doc No: 2015-17730
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. FDA-2015-N-2412
Determination That TESSALON (Benzonatate) Capsules and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
FOR FURTHER INFORMATION CONTACT: Stacy Kane, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6207, Silver Spring, MD 20993-0002, 301-796-8363.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the ``listed drug,'' which is a version of the drug that was previously approved. ANDAs applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).
The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the ``Approved Drug Products with Therapeutic Equivalence Evaluations,'' which is generally known as the ``Orange Book.'' Under FDA regulations, a drug is removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).
Under Sec. 314.161(a) (21 CFR 314.161(a)), the Agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved, (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved, and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for safety or effectiveness reasons, the Agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug.
FDA has become aware that the drug products listed in the table are no longer being marketed. (As requested by the applicant, FDA withdrew approval of NDA 050448 for GRIFULVIN (griseofulvin) Oral Suspension in the Federal Register of August 16, 2001 (66 FR 43017)).
------------------------------------------------------------------------
Application No. Drug Applicant
------------------------------------------------------------------------
NDA 011210............. TESSALON (benzonatate) Pfizer Inc., 1 Giralda
Capsule; Oral 200 Farms, Madison, NJ
milligrams (mg). 07940.
NDA 012093............. ISORDIL (isosorbide Valeant
dinitrate) Tablet; Pharmaceuticals North
Oral 10 mg, 20 mg, 30 America, LLC, 400
mg. Somerset Corporate
Blvd., Bridgewater,
NJ 08807.
NDA 018702............. ACLOVATE (alclometasone Fougera
dipropionate) Pharmaceuticals Inc.,
Ointment; Topical 60 Baylis Rd., P.O.
0.05%. Box 2006, Melville,
NY 11747.
NDA 018707............. ACLOVATE (alclometasone Do.
dipropionate) Cream;
Topical 0.05%.
NDA 018936............. SARAFEM (fluoxetine Eli Lilly and Co.,
hydrochloride (HCl)) Lilly Corp. Ctr.,
Capsule; Oral Indianapolis, IN
Equivalent to (EQ) 10 46285.
mg Base, EQ 20 mg Base.
NDA 018988............. VASOCIDIN (prednisolone Novartis
sodium phosphate; Pharmaceuticals
sulfacetamide sodium), Corp., 105 Eisenhower
Solution/Drops; Pky., 280 Corporate
Ophthalmic, EQ 0.23% Center, Roseland, NJ
phosphate; 10%. 07068.
NDA 019898............. PRAVACHOL (pravastatin Bristol-Myers Squibb
sodium) Tablet; Oral Co., P.O. Box 4000,
10 mg. Princeton, NJ 08543-
4000.
NDA 020092............. DILACOR XR (diltiazem Actavis Laboratories
HCl) Capsule, Extended- UT, Inc., 577 Chipeta
Release; Oral 120 mg, Way, Salt Lake City,
180 mg, 240 mg. UT 84108.
NDA 021551............. HALFLYTELY Braintree
(polyethylene glycol Laboratories, Inc.,
3350; potassium 60 Columbia St., P.O.
chloride; sodium Box 850929,
bicarbonate; sodium Braintree, MA 02185.
chloride) For Solution
and bisacodyl Delayed-
Release Tablets); Oral
210 grams (g); 0.74 g;
2.86 g; 5.6 g; 5 mg.
NDA 021871............. LOESTRIN 24 FE (ethinyl Warner Chilcott Co.
estradiol; LLC, Union Street Rd.
norethindrone acetate) 195 KM 1.1., Fajardo,
Tablet; Oral 0.02 mg; Puerto Rico 00738.
1 mg.
NDA 050448............. GRIFULVIN V Johnson & Johnson
(griseofulvin, Consumer Products
microcrystalline) Co., 199 Grandview
Suspension; Oral 125 Rd., Skillman, NJ
mg/5 milliliters (mL). 08558.
NDA 050719............. HELIDAC (bismuth Prometheus
subsalicylate; Laboratories Inc.,
metronidazole; 9410 Carroll Park
tetracycline HCl) Dr., San Diego, CA
Tablet, Chewable, 92121.
Tablet, Capsule; Oral
262.4 mg; 250 mg, 500
mg.
ANDA 040454............ PROMETHAZINE Teva Pharmaceuticals
HYDROCHLORIDE USA, 425 Privet Rd.,
(promethazine HCl) Horsham, PA 19044.
Injectable; Injection
25 mg/mL, 50 mg/mL.
ANDA 062483............ GRIFULVIN V Valeant
(griseofulvin, Pharmaceuticals
microsize) Suspension; Luxembourg S.a.r.l, C/
Oral 125 mg/5 mL. O Valeant
Pharmaceuticals North
America LLC, 400
Somerset Corporate
Blvd., Bridgewater,
NJ 08807.
Page 42829
ANDA 088762............ PROMETH W/ G&W Laboratories
DEXTROMETHORPHAN Inc.,111 Coolidge
(dextromethorphan St., South
hydrobromide; Plainfield, NJ 07080.
promethazine HCl)
Syrup; Oral 15 mg/5
mL; 6.25 mg/5 mL.
------------------------------------------------------------------------
FDA has reviewed its records and, under Sec. 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the Agency will continue to list the drug products listed in this document in the ``Discontinued Drug Product List'' section of the Orange Book. The ``Discontinued Drug Product List'' identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness.
Approved ANDAs that refer to the NDAs and ANDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs and ANDAs. Additional ANDAs that refer to these products may also be approved by the Agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.
Dated: July 15, 2015.
Leslie Kux,
Associate Commissioner for Policy.
FR Doc. 2015-17730 Filed 7-17-15; 8:45 am
BILLING CODE 4164-01-P
